Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB

Abstract

Background: The systemic immune-inflammation index (SII) has been identified as a predictor of chemotherapy efficacy for a variety of cancers, and we aimed to determine its ability to predict the response to chemotherapy and its long-term prognosis for patients with cervical squamous cell carcinoma (CSCC) who have underwent platinum-based neoadjuvant chemotherapy (NACT).Methods: The date from 210 patients (133 in the training cohort and 77 in the validation cohort) with CSCC who received NACT were analyzed retrospectively. The association between SII and the pathological complete response (pCR) was determined using Pearson’s chi-square test, receiver operating characteristic (ROC) curve, and Logistic regression analysis. The Kaplan-Meier method and Cox proportional regression model were used to assess the relationship between SII and progression-free survival (PFS) or overall survival (OS).Results: The calculated optimal SII cutoff values for pCR and survival were 568.7051 and 600.5683, respectively, and patients were divided into two groups: a low SII group (≤568.7051 or ≤600.5683) and a high SII group (>568.7051 or >600.5683). A high SII was associated significantly with a lower pCR. Further analysis determined that SII was a more efficient predictor of pCR than the prognostic nutritional index, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. Upon multivariate logistic analysis, SII proved to be an independent risk factor to predict the pCR of patients with CSCC. Kaplan-Meier analysis demonstrated that PFS and OS rates were significantly higher in the low-SII group compared with those in the high-SII group. Additional multivariate analysis indicated that the SII is an independent prognostic factor for patients with CSCC treated with NACT.Conclusion: The results confirmed that the pre-treatment SII is not only an independent predictor of pCR but also an independent prognostic factor of CSCC patients treated with platinum based NACT.

The prognostic value of the systemic immune-inflammation index (SII) and red cell distribution width (RDW) in cervical cancer patients treated with definitive radiotherapy.

“…Despite a growing body of evidence, pre-treatment blood parameters are rarely incorporated into the assessment of patient's prognosis. Several indices, including the eosinophil-lymphocytes ratio (ELR) 15 , NLR, PLR, thrombocyte-to-lymphocyte ratio (TLR), and C-reactive protein/albumin ratio (CAR) 16 , or SII 10,15,17 , have been proposed in the literature. Given that the expected survival rate for CRT-treated patients ranges between 15% and 95% 5 , enhancements to the pre-treatment evaluation are essential.…”

The Significance of Preoperative Systemic Immune Inflammation Index in Newly Diagnosed Glioblastoma Patients and the Establishment of a Nomogram

“…Systemic immune-in ammation index (SII) is a novel prognostic marker compared to the previously mentioned markers. In the past, SII has been shown to have a signi cant prognostic effect in a broad range of cancers, including renal cell carcinoma, melanoma, gastric cancer, and cervical cancer, via numerous studies (He et al 2022;Liu et al 2022;Stuhler et al 2022;Susok et al 2022). It is still debatable whether SII can be an essential biomarker for glioma prognosis prediction (Jarmuzek et al 2022;Yilmaz et al 2021;Zhu et al 2021).…”

“…Hepatocellular carcinoma provided the rst evidence of SII's prognostic value as a novel indicator of in ammation(Hu et al 2014). In recent years an increasing number of studies have con rmed the close association of SII with the prognosis of various diseases such as metastatic renal cell carcinoma, non-small cell lung cancer(Liu et al 2019;Wang et al 2019) and cervical cancer(Liu et al 2022). Our group has been working on the survival and prognosis of gliomas.…”

Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer

“…Cancer is associated with not only localized inflammation but also dysregulation of the overall systemic immune response 9 . Inflammation is an essential factor associated with the development, progression, and potential metastasis of CC 10 .…”

“…Furthermore, changes in local and systemic cytokine levels can reflect the immune response of lymphocyte populations induced by cancer cells 25 . CC is associated with inflammation at the site of the lesion, as well as dysregulation of the overall systemic immune response 9 , 10 , 26 .…”